Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Feature

Perspectives
Primary Care-Oriented Pathways to Support Population-Based Payment Models
09/20/2019
Leah M Marcotte, MD
Anders Chen, MD, MHS
Catherine S Hwang, MSPH
Joshua M Liao, MD, MSc
Abstract: While clinical pathways have been identified as a key strategy for succeeding under inpatient episode-based payment models, they have not been widely touted as part of primary care population-based...
Abstract: While clinical pathways have been identified as a key strategy for succeeding under inpatient episode-based payment models, they have not been widely touted as part of primary care population-based...
...
09/20/2019
Journal of Clinical Pathways

Advertisement

Research Reports
Impact of Psychosocial Factors on Health Services Utilization and Cost of Care in Blood and Marrow Transplant Patients
07/08/2019
Yordanka N Koleva, PhD
Lisa C Solursh-Abbrecht, PsyD
Jerrold Yeo, PsyD
Chenguang Zhang, MS
Nakhle Saba, MD
Hana Safah, MD
Abstract: Hematopoietic stem cell transplant (HSCT) for blood and bone marrow disorders is a costly procedure that requires complex treatment regimens. In addition to disease-related factors, comorbidity and...
Abstract: Hematopoietic stem cell transplant (HSCT) for blood and bone marrow disorders is a costly procedure that requires complex treatment regimens. In addition to disease-related factors, comorbidity and...
...
07/08/2019
Journal of Clinical Pathways
Research Reports
Drug Costs vs Probability of Survival in Lung Cancer: Impact of Dosage, Duration, and Immune Checkpoint Inhibitor Combinations
06/18/2019
Helmy M Guirgis, MD
Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-small cell lung cancer (amNSCLC). There is an unmet need...
Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-small cell lung cancer (amNSCLC). There is an unmet need...
...
06/18/2019
Journal of Clinical Pathways
Perspectives
On the Horizon for Value-Based Oncology Care: Predictive Analytics, Novel Therapy Pricing Pressures, New Payment Models, and a Rise in Complex Data Sources
06/18/2019
Charles Saunders, MD
Jennifer Webster, MS
Abstract: January 2019 represented another major inflection point for the Oncology Care Model (OCM), marking the halfway point of the 5-year program. Overall, while OCM participants have expressed concerns about...
Abstract: January 2019 represented another major inflection point for the Oncology Care Model (OCM), marking the halfway point of the 5-year program. Overall, while OCM participants have expressed concerns about...
...
06/18/2019
Journal of Clinical Pathways

Advertisement

From the Field
The Supportive Care of Oncology Patients (SCOOP) Pathway: A Novel Approach to Improving the Patient Experience in the Curative Treatment of Cancer
05/15/2019
Christopher Koprowski, MD, MBA
Nicholas Petrelli, MD, FACS
Edith J Johnson, PhD, MBA
Karen Sites, MSN, RN, OCN
Abstract: It was hypothesized that by introducing more intense supportive care and enhanced nurse navigation in high-acuity curable cancer patients, we could achieve the same results noted in patients with advanced...
Abstract: It was hypothesized that by introducing more intense supportive care and enhanced nurse navigation in high-acuity curable cancer patients, we could achieve the same results noted in patients with advanced...
...
05/15/2019
Journal of Clinical Pathways
Perspectives
Value-Based Management of Clinical Pathways: An Applied Framework
05/15/2019
Christopher P Chen, MD, MBA
Leah M Marcotte, MD, FACP
Kimberley Herner, MD
Joshua M Liao, MD, MSc, FACP
Abstract: For health care organizations, clinical pathways have historically been important tools for translating medical evidence into practice and delivering high-quality, cost-conscious (ie, high-value) care....
Abstract: For health care organizations, clinical pathways have historically been important tools for translating medical evidence into practice and delivering high-quality, cost-conscious (ie, high-value) care....
...
05/15/2019
Journal of Clinical Pathways
Research Reports
Barriers to Lymphoma Clinical Practice Guideline Adherence: A Pilot Mixed-Methods Research Study
04/16/2019
Mihaela C Munteanu, EdD, MS
John M Burke, MD
Abstract: Little is published about adherence barriers to lymphoma clinical practice guidelines (CPGs). This article examines the most frequent barriers to adherence to lymphoma CPGs. An explanatory sequential...
Abstract: Little is published about adherence barriers to lymphoma clinical practice guidelines (CPGs). This article examines the most frequent barriers to adherence to lymphoma CPGs. An explanatory sequential...
...
04/16/2019
Journal of Clinical Pathways

Advertisement

Case Study
Patient-Reported Outcomes: Investing in Real-Time Intervention to Improve Care
04/16/2019
Diane Denny, DBA, MHA, FACHE, CPHQ, CPPS
Brandon Bosch, MPH
Morgan Hannaford, MA
Scott R Hartman, MS, PMP
Abstract: A geographically dispersed network of hospitals began the journey to integrate patient-reported outcome (PRO) data in the form of quality-of-life measurement into daily operations beginning in 2012, moving...
Abstract: A geographically dispersed network of hospitals began the journey to integrate patient-reported outcome (PRO) data in the form of quality-of-life measurement into daily operations beginning in 2012, moving...
...
04/16/2019
Journal of Clinical Pathways
Research Reports
Impact of Psychosocial Factors on Health Services Utilization and Cost of Care in Blood and Marrow Transplant Patients
03/13/2019
Yordanka N Koleva, PhD
Lisa C Solursh-Abbrecht, PsyD
Jerrold Yeo, PsyD
Chenguang Zhang, MS
Nakhle Saba, MD
Hana Safah, MD
Abstract: Hematopoietic stem cell transplant (HSCT) for blood and bone marrow disorders is a costly procedure that requires complex treatment regimens. In addition to disease-related factors, comorbidity and...
Abstract: Hematopoietic stem cell transplant (HSCT) for blood and bone marrow disorders is a costly procedure that requires complex treatment regimens. In addition to disease-related factors, comorbidity and...
...
03/13/2019
Journal of Clinical Pathways
Perspectives
Advocating for New Patient-Centered Tools for Value-Based Treatment Choices in Oncology
03/13/2019
Jalpa A Doshi, PhD
Ellen Miller-Sonet, MBA, JD
Justin T Puckett
Henry A Glick, PhD
Abstract: The cost of medical drugs continues to increase, and costs of novel therapies for oncology are particularly expensive—for patients as well as health systems in general. Many health care stakeholders are...
Abstract: The cost of medical drugs continues to increase, and costs of novel therapies for oncology are particularly expensive—for patients as well as health systems in general. Many health care stakeholders are...
...
03/13/2019
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use